Oncology Xagena
An interim analysis of a Phase III study of Avastin ( Bevacizumab ) in combination with Paclitaxel and Carboplatin in advanced, non-small cell lung cancer ( NSCLC ) met its primary efficacy endpoint ...
ProMune is a synthetic agonist for Toll-like receptor 9 ( TLR9 ). By stimulating TLR9, ProMune acts directly and selectively on plasmacytoid dendritic cells and B cells to reverse immune tolerance to ...
Alpha-tocopherol ( Vitamin-E ) supplementation produced unexpected adverse effects on the occurrence of second primary cancers and on cancer-free survival in patients with head and neck cancer, treate ...
Erlotinib ( Tarceva ) is the first drug and the only EGFR-targeted treatment shown to prolong survival in a phase III trial ( PA3 ) when added to standard of care ( Gemcitabine ) for the treatment of ...
High copy number of the epidermal growth factor receptor ( EGFR ) may be an effective predictor of Gefitinib ( Iressa ) efficacy in non-small-cell lung cancer. Gefitinib is a selective inhibitor o ...
A randomized study of Erlotinib ( Tarceva ) plus Gemcitabine met its primary endpoint by demonstrating a statistically significant 23.5 percent improvement in overall survival ( or a hazard ratio of 0 ...
Data from a study ( E4599 ) of Bevacizumab ( Avastin ) plus Paclitaxel and Carboplatin in first-line non-squamous, non-small cell lung cancer ( NSCLC ) showed the study met its primary efficacy endpoi ...
An experimental compound, ABT-737, that blocks the action of a class of proteins known as the Bcl-2 family, may prove to be a valuable tool in the fight against cancer. The Bcl-2 family of protein ...
AstraZeneca announced that after discussions with the FDA ( U.S. Food and Drug Administration ), the company is making a labeling change to Iressa ( Gefitinib ). Based on the FDA's assessment of cu ...
First-degree relatives of black individuals with early-onset lung cancer have twice the risk of lung cancer than first-degree relatives of white individuals with early-onset lung cancer. Cigarette ...
Tarceva ( Erlotinib ) has received a positive recommendation from the European Committee for Medicinal Products for Human Use ( CHMP ) for the treatment of non-small cell lung cancer, the most common ...
The University of Texas M. D. Anderson Cancer Center has reactivated a lung cancer chemoprevention trial studying Celecoxib, an anti-inflammatory medication also known as Celebrex. M. D. Anderson v ...
A study, led by Canadian researchers, has demonstrated that Erlotinib ( Tarceva ) increases survival in patients with advanced non-small cell lung cancer who typically have no other treatment options. ...
Researchers at Cedars-Sinai Medical Center have identified a protein called EMP-1 that is present in the tumors of patients who fail to respond to treatment with Gefitinib ( Iressa ), a drug used in t ...
Surgeons at the Oregon Health & Science University Digestive Health Center have developed a new technique that makes feasible and safe a potentially lifesaving and noninvasive surgical procedure known ...
